Clinical trials: Schizophreniform Disorder
Schizophrenia, Schizophreniform Disorder
rTMS in First Episode Psychosis
This study proposes to examine the application of rTMS for the treatment of cognitive dysfunction in FEP. This is an important population for study because if effective, rTMS may represent a preventative treatment for the…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- EmeraldThunder (NCT02131129)
- Testing
- rTMS
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Schizophrenia Spectrum Disorders, Schizophrenia
Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis
This study is to evaluate the safety and efficacy of Virtual Reality Mindfulness in Patients With Psychosis.
- Conditions
- Schizophrenia Spectrum Disorders, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT05784948
- Testing
- Virtual Reality Mindfulness Treatment, Experience relaxing scenery and music
- Where
- South Korea
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Schizophrenia, Schizophreniform Disorders
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness
- Conditions
- Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
- Trial name
- NCT03187769
- Testing
- ALKS 3831, Olanzapine
- Where
- 57 sites in United States, Austria and 10 more
- Volunteers
- 426 people
- Sponsor
- Alkermes, Inc.
Psychosis, Schizophrenia
Levetiracetam in Early Psychosis
In order to establish target engagement and identify an effective dose the investigators will conduct a placebo-controlled single-dose parallel group trial of levetiracetam 185 mg and 500 mg in 24 medication-naïve early psychosis…
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
- Trial name
- NCT03129360
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Schizophrenia, Schizoaffective Disorder
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial
Purpose: To test the effectiveness of an exercise intervention that combines group walking, activity tracking, and heart rate monitoring (i.e.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorders
- Trial name
- (PACE-life (NCT04173572)
- Testing
- PACE-Life, Exercise Intervention
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
Since side effects of antipsychotics, dopamine D2 receptor blockers, frequently occur in older patients with schizophrenia and the risk is dose dependent, clinical guidelines universally advocate the use of lower doses.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT00716755
- Testing
- Risperidone/Olanzapine and PET scans
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Research Into Antipsychotic Discontinuation and Reduction Trial
Psychosis and schizophrenia are common and costly mental health problems. Psychosis is the name given to a group of mental conditions in which cause people to perceive or interpret things differently from those around them.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Schizophreniform Disorders
- Trial name
- NCT03559426
- Testing
- Antipsychotic Reduction, Antipsychotic Maintenance
- Where
- United Kingdom
- Volunteers
- 253 people
- Sponsor
- University College, London
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
This a randomized double-blind placebo controlled trial which aims to determine the beneficial effects of minocycline augmentation to clozapine in partial responders to Treatment Resistant Schizophrenia (TRS).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT02533232
- Testing
- Minocycline
- Where
- 4 sites in Pakistan
- Volunteers
- 60 people
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia, Schizophreniform Disorders
Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.
This study aims to determine if the addition of Sodium Benzoate and / or NAC to TAU will be acceptable and tolerable and result in overall improvement of symptoms, social and cognitive functioning in patients with early…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder
- Trial name
- NCT03510741
- Testing
- Sodium Benzoate, N-Acetylcysteine, Sodium Benzoate Plus N-Acetylcysteine
- Where
- 5 sites in Pakistan
- Volunteers
- 64 people
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia, Schizoaffective Disorder
Varenicline Adjunctive Treatment in Schizophrenia
The principal aim of the project is to conduct an off-label adjunctive clinical trial evaluating varenicline as a treatment for core neurobiological and clinical deficits in schizophrenia, in addition to evaluating for smoking…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00492349
- Testing
- Varenicline
- Where
- 3 sites in United States
- Volunteers
- 91 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
An Integrated Program for the Treatment of First Episode of Psychosis
The purpose of this study is to determine how services should be provided to reduce symptoms and improve life functioning for adolescents and adults who have been recently diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder
- Trial name
- RAISE ETP (NCT01321177)
- Testing
- Integrated Treatment, Community Care
- Where
- 33 sites in United States
- Volunteers
- 404 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
There is increasing clinical and molecular evidence for the role of hormones and specifically estrogen and its receptor in schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS
- Trial name
- RAPSODI (NCT03043820)
- Testing
- Raloxifene
- Where
- Netherlands
- Volunteers
- 110 people
- Sponsor
- Iris Sommer
Schizophrenia, Schizoaffective Disorder
Naltrexone for Antipsychotic-Induced Weight Gain
This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NTX (NCT01866098)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophrenia, Schizoaffective Disorder
Brain Circuits in Schizophrenia and Smoking
The principle aim of the project is to identify the key brain circuits associated with smoking and especially smoking in high risk population.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT01425684
- Where
- United States
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophreniform Disorders
Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy
To test the feasibility of a clinical trial implementing I-CAT, a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g.
- Trial name
- I-CAT (NCT03067311)
- Testing
- I-CAT, Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizophreniform Disorder
Biomarkers in First Episode Schizophrenia
This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type
- Trial name
- NCT02033382
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Schizophrenia, Schizoaffective Disorder
Simvastatin Addition for Patients With Recent-onset Schizophrenia
Rationale: There is ample evidence that inflammatory processes play a role in the pathophysiology of schizophrenia. Although Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have been shown to be able to reduce symptoms in these…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS
- Trial name
- NCT01999309
- Testing
- Simvastatin
- Where
- 2 sites in Netherlands
- Volunteers
- 121 people
- Sponsor
- Iris Sommer
Schizoaffective and Schizophreniform Disorders, Schizophrenia
Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia
The aim of this study is to evaluate the overall effectiveness of Ondansetron as an adjunctive or "add-on" medication in the treatment of Schizophrenia. This study is a double blind, placebo-controlled, randomised, 12 week trial.
- Trial name
- NCT01121042
- Testing
- Ondansetron
- Where
- Australia
- Volunteers
- 85 people
- Sponsor
- Bayside Health
Schizophrenia, Schizoaffective Disorder
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life
Purpose: To develop and test the feasibility of an exercise intervention that combines group walking, activity tracking, and heart rate monitoring, and determine the effectiveness of this intervention on the physical and mental…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorder
- Trial name
- PACE-life (NCT03757988)
- Testing
- Exercise Intervention- PACE-Life
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill